Tomislav Sokol· PPE

Nuanced

Of 56 approved oncology drugs approved between 2020 and 2023, 54 are available in Germany while only two are available in Malta

Omissions

• The specific figure of 56 oncology drugs could not be verified through available sources
• The OECD report from September 2024 cites 46 oncology medicines, not 56, with 45 available in Germany and 1 in Malta
• The EFPIA W.A.I.T. Indicator 2024 survey mentions 173 innovative medicines (all therapeutic areas) approved between 2020-2023, not specifically 56 oncology drugs
• The MEP did not cite a source for these specific figures
• Different methodologies for counting 'available' medicines (reimbursed vs. marketed vs. authorized) may explain the discrepancy

Sources

• PrimaryOECD - Access to oncology medicines in EU and OECD countriesOut of 46 medicines (98%) being reimbursed in Germany to only one medicine (2%) being reimbursed in Malta
• SecondaryEFPIA - Patients W.A.I.T. Indicator 2024 SurveyInformation on the availability of 173 innovative medicines with central-marketing authorisation between 2020 and 2023